Country Demographics 1,2,3,7,9					
Total population (2020) <sup>9</sup>	59,190				
Urban population (% of total, 2020) 9	70%				
Health expenditure per capita (\$US, 2017) <sup>2</sup>	\$642.20				
Health expenditure, total (% of GDP, 2017) <sup>2</sup>	16.4%				
Total births (2019) <sup>1</sup>	1,090				
Surviving infants (2019) 1	1,068				
Life expectancy at birth (years, 2020) <sup>7</sup>	74.1 yrs				
Number of districts (2013) <sup>3</sup>	3				

HBsAg Prevalence <sup>6</sup>					
Pre-vaccine HBsAG+ (%)	12%				

Liver Cancer as Cause of Cancer Death (in Men) <sup>5</sup>					
Year: 2018	Ranking: NR				


<b>2019 Co</b>	untry Comp	parison in Western Paci	fic Region (37 Member States/	∕Areas)⁴
		Normalian of magnetical states		Laurant M/

	Marshall Islands  Number of member states with WHO-UNICEF estimated coverage		Highest WHO-UNICEF estimated coverage in WPR	Lowest WHO-UNICEF estimated coverage in WPR		
HepB3 <sup>4</sup>	82%	27	99% (Brunei Darussalam, China, Fiji, Japan, Niue, Tonga)	35% (Papua New Guinea)		
HepB BD <sup>4</sup>	98%	24	99% (Brunei Darussalam, Cook Islands, Fiji, Kiribati, Malaysia, Nauru, Niue, Palau, Tonga)	25% (Papua New Guinea)		


## Hepatitis B Immunization Coverage<sup>4</sup>


· · · · · · · · · · · · · · · · · · ·																				
	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019
HepB3 <sup>4</sup>	38%	76%	80%	74%	72%	89%	97%	93%	97%	99%	97%	89%	80%	80%	79%	85%	73%	82%	84%	82%
HepB BD <sup>4</sup>	99%	99%	99%	99%	99%	99%	99%	99%	99%	99%	99%	99%	96%	92%	87%	99%	99%	97%	94%	98%
DTP3 <sup>4</sup>	39%	48%	80%	68%	64%	77%	74%	93%	95%	96%	94%	87%	80%	79%	78%	85%	71%	80%	81%	79%
BCG⁴	89%	99%	90%	93%	91%	93%	92%	92%	95%	98%	99%	98%	97%	93%	89%	99%	94%	92%	98%	89%

## Marshall Islands: HepB3 vs. DTP3









Asian Liver Center

National Policies on Hepatitis B Screening for Pregnant Women				
Mandatory HepB screening in all pregnant women (Y/N)				
-If Y, mandatory reporting of HBs-Ag positive pregnant women to public health department (Y/N)				
HBIG administered with HepB BD to infants born to HBsAg positive women (Y/N)				
- If Y, is it free? (Y/N)				

National Policies on Hepatitis B Immunization <sup>8</sup>	
Universal newborn HepB immunization (Y/N) 8	Υ
- If Y, year introduced <sup>8</sup>	1988
-HepB3 nationwide <sup>8</sup>	NR
-Free for all newborns (Y/N)	
-If free, state year introduced:	
Catch-up immunization program for unvaccinated children (Y/N)	
- If Y, year introduced	
-Free for all unvaccinated children (Y/N)	
-If free, state year introduced:	
Immunization program for health care workers (Y/N)	
- If Y, year introduced	
-Free for all health care workers(Y/N)	
-If free, state year introduced:	
HepB newborn immunization included in multiyear plan for EPI (Y/N)	
HepB BD in schedule (Y/N) <sup>8</sup>	Y
Systems to monitor HepB BD <sup>8</sup>	Hospitals, HCs, Homes
Systems to deliver HepB BD <sup>8</sup>	Hospitals, HCs, Homes
HepB vaccine funding other than country government (Y/N)	
-If Y, please specify funding source:	

National Policies on Chronic Hepatitis B Treatme	ent	Certification Status <sup>1</sup>			
Treatment for chronic HBV infection covered (Y/N)		Year certification report received	Pending (2019)		
- If Y, year introduced		Year certification panel convened	NR		
-Interferon (Y/N)		Year certification approved	NR		
-Oral antiviral (Y/N)		Approved with prevalence <1% or <2%?	NR		



Asian Liver Center